D. E. Shaw & Co., Inc. Tricida, Inc. Transaction History

D. E. Shaw & Co., Inc.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$8.51 - $13.6 $17,615 - $28,152	-2,070 Reduced 0.39%	524,266 $5.5 Million
Q2 2022 Aug 15, 2022	SELL	$7.31 - $11.85 $1.49 Million - $2.41 Million	-203,776 Reduced 27.91%	526,336 $5.1 Million
Q1 2022 May 16, 2022	SELL	$7.35 - $10.63 $1.16 Million - $1.67 Million	-157,509 Reduced 17.75%	730,112 $6 Million
Q4 2021 Feb 14, 2022	BUY	$4.19 - $9.56 $52,253 - $119,222	12,471 Added 1.43%	887,621 $8.49 Million
Q3 2021 Nov 15, 2021	SELL	$3.56 - $4.64 $542,789 - $707,456	-152,469 Reduced 14.84%	875,150 $4.06 Million
Q2 2021 Aug 16, 2021	SELL	$3.95 - $5.41 $337,681 - $462,495	-85,489 Reduced 7.68%	1,027,619 $4.44 Million
Q1 2021 May 17, 2021	BUY	$4.52 - $7.8 $1.51 Million - $2.6 Million	333,529 Added 42.78%	1,113,108 $5.89 Million
Q4 2020 Feb 16, 2021	BUY	$4.37 - $9.46 $3.41 Million - $7.37 Million	779,579 New	779,579 $5.5 Million
Q3 2020 Nov 16, 2020	SELL	$8.56 - $26.93 $429,052 - $1.35 Million	-50,123 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$21.21 - $31.55 $286,165 - $425,672	-13,492 Reduced 21.21%	50,123 $1.38 Million
Q1 2020 May 15, 2020	BUY	$18.43 - $38.04 $649,491 - $1.34 Million	35,241 Added 124.2%	63,615 $1.4 Million
Q4 2019 Feb 14, 2020	BUY	$29.6 - $43.71 $839,870 - $1.24 Million	28,374 New	28,374 $1.07 Million
Q3 2019 Nov 14, 2019	SELL	$29.87 - $42.22 $1.32 Million - $1.86 Million	-44,118 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$31.16 - $39.46 $1.37 Million - $1.74 Million	44,118 New	44,118 $1.74 Million

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.